HIV reservoir study in men on Biktarvy
Part of Infections clinical trials.
This study looks at where HIV hides in the body (called the viral reservoir) in men whose HIV is well controlled with Biktarvy. Researchers want to see how the levels of HIV medicines in the body relate to these hidden virus cells, which may help improve future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a man aged 18 or older.
- You must have HIV-1 (not HIV-2) and be on Biktarvy as your first HIV treatment.
- Your HIV viral load must be undetectable (below 50 copies/mL) starting 6 months after you began treatment, and that must continue for at least a year.
- Your blood clotting tests (called TP and TCA) and platelet counts must be normal at screening.
- You cannot take blood thinners or have hemophilia, because the study involves a tissue biopsy (taking a small sample).
- You cannot be taking certain other medicines, such as carbamazepine, phenytoin, rifampicin, or St. John's Wort.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well women with HIV stay in care while taking the medication Biktarvy (a combination of three drugs in one pill). It aims to understand their health outcomes and support better care.
This trial tests the medication Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) for people with HIV who have stopped taking their antiretroviral therapy (ART) for at least 12 weeks and are ready to restart treatment. It aims to see how well the medication works when restarting care.
This study tests a new HIV medication (GS-3242) combined with lenacapavir against your current Biktarvy regimen. Both are all-oral treatments for people whose HIV is well-controlled.
This study compares how active the immune system is and how large the “hidden” HIV reservoir is in people on two different HIV treatment types. It may help researchers understand whether staying on a tenofovir-containing regimen leads to better control of HIV hiding in the body.
This study tests whether combining two or more investigational drugs that can activate the hidden HIV reservoir in your body might help eliminate it. The goal is to see if this approach is safe and could help lead to a cure for HIV.
This study looks at how HIV can stay hidden in the gut even when antiretroviral therapy keeps the virus under control. By examining tissue from a routine colonoscopy, researchers hope to learn more about why HIV persists, which could lead to better treatments.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.